Dexcom Products

Proven Outcomes

DIaMonD study shows Dexcom CGM System* use results in significant benefits for MDI patients.

You are here

Dexcom CGM Use Lowers A1C by 1.0%<sup>1</sup>

Dexcom Continuous Glucose Monitoring (CGM) System users on a multiple daily injections (MDI) insulin regimen showed an average A1C reduction of 1% after 24 weeks of regular use, compared to baseline. Additionally, 52% of subjects in the study had a ≥1% A1C reduction.1

Significant A1C Reduction in Uncontrolled Patients

Participants with a baseline A1C of 8.5% showed an average 1.3% reduction.1

High Rate of Adherence

At week 24, 93% of study participants were still using the Dexcom CGM System ≥ 6 days/week.1

Increased Time Spent in Range

The Dexcom CGM System significantly increased time spent in range from baseline (70-80 mg/dL)—an additional 1.2 median hours (+72 minutes).1

Reduction of Hypoglycemia

CGM users showed a 79% reduction in hypoglycemia at night (11 median minutes).1

1Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017;317(4):371-378.

*Study conducted using the Dexcom G4® PLATINUM CGM System, which uses the same software as the Dexcom G5® Mobile CGM System.

Request Dexcom Information for Your Practice

If you are a clinician and want to learn more about Dexcom’s Continuous Glucose Monitoring Systems, please fill out the form and a Dexcom representative will contact you.

If you are a Dexcom User or Patient, please contact Dexcom here.

The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.